Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 10,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $17.04, for a total transaction of $170,400.00. Following the completion of the sale, the insider now owns 183,266 shares in the company, valued at approximately $3,122,852.64. This trade represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Centessa Pharmaceuticals Stock Up 2.1 %

Shares of NASDAQ:CNTA opened at $17.26 on Friday. The company has a 50 day moving average price of $16.71 and a two-hundred day moving average price of $13.81. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market capitalization of $2.27 billion, a PE ratio of -11.28 and a beta of 1.52. Centessa Pharmaceuticals plc has a 52 week low of $6.65 and a 52 week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. First Light Asset Management LLC grew its holdings in Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after buying an additional 1,778,515 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after acquiring an additional 1,625,000 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $20,698,000. Franklin Resources Inc. grew its position in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after acquiring an additional 1,145,823 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its position in Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after purchasing an additional 987,997 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CNTA shares. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. B. Riley assumed coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective on the stock. BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Finally, Jefferies Financial Group increased their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.